本文選題：原發(fā)性肝癌 + 消積化瘀丸　； 參考：《廣西中醫(yī)藥大學(xué)》2017年碩士論文

【摘要】：目的:通過觀察、分析消積化瘀丸聯(lián)合TACE對(duì)原發(fā)性肝癌患者免疫功能、AFP、肝功能、不良反應(yīng)、KPS評(píng)分、中醫(yī)證候療效等各方面的影響,評(píng)估消積化瘀丸聯(lián)合介入治療原發(fā)性肝癌的療效及安全性。為中醫(yī)、中藥在原發(fā)性肝癌介入術(shù)后的臨床應(yīng)用上提供新的研究思路和依據(jù)。方法:將60例原發(fā)性肝癌患者按入院順序,分為治療組30例,對(duì)照組30例,治療組的1例因未能遵囑服用中藥被剔除。最后納入臨床觀察的病例共計(jì)59例,其中對(duì)照組30例,治療組29例。治療組予以消積化瘀丸聯(lián)合TACE治療,對(duì)照組則單純TACE治療。分別在治療前,治療后觀察患者AFP、免疫功能指標(biāo)、肝功能。治療后評(píng)估KPS評(píng)分、中醫(yī)證候療效、術(shù)后不良反應(yīng)。治療前及治療后復(fù)查肝臟CT評(píng)價(jià)實(shí)體瘤近期療效。結(jié)果:1.兩組實(shí)體瘤近期療效比較,差異無統(tǒng)計(jì)學(xué)意義(p0.05);2.兩組間KPS評(píng)分療效比較,差異無統(tǒng)計(jì)學(xué)意義(p0.05);3.兩組T淋巴細(xì)胞亞群指標(biāo)變化比較,治療組治療后CD3+、CD4+、CD8+及CD4+/CD8+比值較治療前升高,明顯優(yōu)于對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義(p0.05);4.兩組患者治療后,對(duì)于AFP400 ng/m L,兩組并沒有統(tǒng)計(jì)學(xué)意義(p0.05),而AFP≥400 ng/mL中,治療組下降水平較對(duì)照組明顯(p0.05),說明差異有統(tǒng)計(jì)學(xué)意義;5.兩組中醫(yī)證候療效比較,治療組相比于照組改善明顯,具有統(tǒng)計(jì)學(xué)意義(p0.05);6.兩組術(shù)后1周肝功能對(duì)比沒有統(tǒng)計(jì)學(xué)意義(p0.05);7.兩組術(shù)后均出現(xiàn)了白細(xì)胞改變、發(fā)熱、惡心嘔吐、腹痛,治療組較對(duì)照組在腹痛改善上更明顯(p0.05)。結(jié)論:原發(fā)性肝癌患者TACE后聯(lián)合消積化瘀丸治療,較單純TACE治療可以提高機(jī)體免疫功能及中醫(yī)證候療效、改善患者腹痛癥狀、降低AFP水平。
[Abstract]:Objective: through observation, the effect and safety of Xiao Ji Huayu pill combined with TACE on the immune function, AFP, liver function, adverse reaction, KPS score and TCM syndrome were evaluated, and the efficacy and safety of the combined interventional therapy for primary liver cancer were evaluated. Methods: to provide new research ideas and basis. Methods: 60 cases of primary liver cancer were divided into 30 cases in the treatment group, 30 cases in the control group, and 30 cases in the control group, and 1 cases in the treatment group were excluded because of failure to take the Chinese medicine. Finally, 59 cases were included in the clinical observation, of which 30 cases in the control group and 29 cases in the treatment group. The treatment group was treated with Xiao Ji Huayu pill combined T ACE treatment, the control group was only TACE treatment. Before treatment, the patients' AFP, immune function index, liver function were observed after treatment. After treatment, the KPS scores, TCM syndromes, and postoperative adverse reactions were evaluated. Before and after treatment, the liver CT was reviewed to evaluate the short-term curative effect of solid tumor in the liver CT. Conclusion the difference was not statistically significant between the 1. groups of two groups of solid tumors. Significance (P0.05); 2. in the two groups, the effect of KPS score was not statistically significant (P0.05); 3. two groups of T lymphocyte subsets were compared, and the ratio of CD3+, CD4+, CD8+ and CD4+/CD8+ in the treatment group was higher than that before treatment, obviously superior to the control group, and the difference was statistically significant (P0.05); the 4. two groups were treated with ng/m L, two groups after treatment. There was no statistical significance (P0.05), but in AFP > 400 ng/mL, the decrease level of the treatment group was significantly higher than that of the control group (P0.05), indicating that the difference was statistically significant. 5. the two groups of TCM syndromes were compared, and the treatment group was significantly improved compared with the photo group (P0.05); 6. two groups had no statistical significance (P0.05) in the 1 weeks after operation (P0.05); 7. two. Leukocyte change, fever, nausea and vomiting, abdominal pain were found in the group after operation, and the treatment group was more obvious than the control group (P0.05). Conclusion: the treatment of primary liver cancer patients after TACE combined with the treatment of eliminating stasis and stasis can improve the immune function and the curative effect of the TCM syndrome, improve the symptoms of abdominal pain and reduce the level of AFP in the patients.
【學(xué)位授予單位】：廣西中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R735.7

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 鄧蘭;蔣益蘭;吳文清;周美秀;江摩;彭國(guó)林;;FOLFOX4方案化療對(duì)原發(fā)性肝癌患者的臨床效果及預(yù)后影響因素分析[J];實(shí)用癌癥雜志;2016年12期

2 黃智清;張誠(chéng)華;施建設(shè);陳淑蘭;;腹腔鏡肝癌切除術(shù)的臨床療效及對(duì)免疫功能影響的研究[J];中國(guó)現(xiàn)代普通外科進(jìn)展;2016年11期

3 ;2016年原發(fā)性肝癌放療共識(shí)[J];中華放射腫瘤學(xué)雜志;2016年11期

4 厲英超;米琛;薛揮;李偉之;李培杰;呂良山;;介入化療栓塞治療對(duì)原發(fā)性肝癌患者細(xì)胞免疫功能的影響[J];重慶醫(yī)學(xué);2016年31期

5 向倫建;李建偉;陳健;范毓東;鄭樹國(guó);;腹腔鏡肝切除術(shù)在肝細(xì)胞癌中的應(yīng)用[J];中華肝臟外科手術(shù)學(xué)電子雜志;2016年05期

6 沈強(qiáng);許峗;王能;盛月紅;錢國(guó)軍;;射頻消融治療超過米蘭標(biāo)準(zhǔn)肝細(xì)胞肝癌的長(zhǎng)期療效研究[J];中國(guó)微創(chuàng)外科雜志;2016年09期

7 李明輝;劉記恩;張貴堂;劉紅波;馮運(yùn)章;;射頻消融治療肝癌合并脾功能亢進(jìn)[J];現(xiàn)代腫瘤醫(yī)學(xué);2016年19期

8 姜增凱;葉曉歌;陳琴華;;阿帕替尼對(duì)肝癌細(xì)胞增殖和遷移能力的影響研究[J];中國(guó)臨床藥理學(xué)雜志;2016年15期

9 寇小妮;郝明霞;解新科;暢輝;;八珍湯在原發(fā)性肝癌介入治療后的應(yīng)用[J];現(xiàn)代腫瘤醫(yī)學(xué);2016年18期

10 李子杰;葉維寶;黎國(guó)強(qiáng);覃塘棉;;肝動(dòng)脈化療栓塞術(shù)治療原發(fā)性肝癌臨床觀察[J];中國(guó)現(xiàn)代醫(yī)藥雜志;2016年07期

，

本文編號(hào)：2117813